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Ϫ/Ϫ cells, there is no change in ENT2 or ENBT1, resulting in a very low level of nucleoside uptake in these cells, but a high capacity for nucleobase accumulation. Whereas there were no significant changes in nucleoside transporter subtype expression, there was a dramatic increase in adenosine deaminase and adenosine A 2a receptors (both transcript and protein) in the ENT1 Ϫ/Ϫ tissues compared with WT. These changes in adenosine deaminase and A 2a receptors likely reflect adaptive cellular mechanisms in response to reduced adenosine flux across the membranes of ENT1 Ϫ/Ϫ cells. Our study also revealed that mouse MVECs have a nucleoside/nucleobase transport profile that is more similar to human MVECs than to rat MVECs. Thus mouse MVECs from transgenic animals may prove to be a useful preclinical model for studies of the effects of purine metabolite modifiers on vascular function. adenosine; microvasculature; heart; transgenic; equilibrative nucleoside transporter ALL MAMMALIAN CELLS express at least one form of equilibrative transporter responsible for the cellular uptake and release of endogenous nucleosides such as adenosine. The predominant transporters are equilibrative nucleoside transporter subtypes 1 (ENT1; SLC29A1) and 2 (ENT2; SLC29A2) (3) . The inhibition of ENTs has been shown to enhance the cardioprotective (21) and neuroprotective (13) actions of adenosine. These transporters are also responsible for the cellular uptake of cytotoxic nucleoside analogs used to treat cancer and viral infections (25) .
An ENT1-null (ENT1 Ϫ/Ϫ ) mouse model has been generated by Choi and colleagues (10) . The ENT1 Ϫ/Ϫ mice are phenotypically normal with the only difference from wild-type (WT) littermates being a slight (Ͻ10%) decrease in body weight and some differences in their behavioral characteristics. The ENT1-null mice are less sensitive to the intoxicating effects of ethanol compared with their WT littermates (10) , and they also display less anxiety-like behavior (9) . It has been noted that there is less tonic A 1 adenosine receptor signaling in the brains of ENT1
Ϫ/Ϫ mice (10), reflecting either reduced extracellular adenosine levels or a decreased sensitivity of the receptor to adenosine, suggesting that ENT1 plays an important role in modulating the interaction of adenosine with its concomitant receptors in the central nervous system.
In addition to its regulatory activities in the nervous system, adenosine is well established as an endogenous cardioprotective agent via interactions with cardiomyocytes and is also a potent vasodilator through actions on vascular smooth muscle and endothelial cells (18) . The availability of ENT1 Ϫ/Ϫ mice will now allow an in-depth examination of the role of ENT1 (and the effects of its absence) in adenosine metabolism and bioactivity in the various cell types that constitute the cardiovascular system under both normal and pathophysiological conditions. We have recently published the results of a study based on cardiomyocytes isolated from WT and ENT1 Ϫ/Ϫ mice (22) . The present study extends this work to an examination of the impact of ENT1 loss on the nucleoside flux and metabolism in microvascular endothelial cells (MVECs).
Previous studies from our laboratory have established that rat MVECs express high levels of both ENT1 and ENT2 (2), whereas human MVECs express predominantly the ENT1 subtype of nucleoside transporter (6) . MVECs are considered to be the major site of accumulation and metabolism of the adenosine released into the interstitial space by myocytes during periods of high energy demand in heart and skeletal muscle (11) ; therefore, in the absence of biological compensation, one might expect the loss of ENT1 to have dramatic effects on the vascular actions of adenosine.
In this communication, we describe the nucleoside and nucleobase transport profile of MVECs derived from skeletal muscle of ENT1 Ϫ/Ϫ mice and their WT littermate controls. [5,4-d] pyrimidine}, collagenase, trypsin, and BSA were obtained from Sigma-Aldrich (St. Louis, MO). All cell culture media, fetal bovine serum (FBS), culture grade Dulbecco's PBS, trypsin-EDTA, antibiotic/antimycotic (penicillin, streptomycin, and amphotericin B), and heparin were purchased from GIBCO/BRL (Burlington, ON, Canada). Endothelial cell growth supplement (ECGS) was supplied by Beckton Dickinson (Oakville, ON, Canada). Rabbit polyclonal anti-adenosine deaminase (ADA), goat polyclonal anti-ENT3, rabbit polyclonal anti-adenosine receptor A3, and donkey anti-goat horseradish peroxidase conjugated antibodies were all from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antiadenosine receptor A2a and rabbit-anti mouse horseradish peroxidaseconjugated and mouse anti-rabbit horseradish peroxidase-conjugated antibodies were from Abcam (Cambridge, MA). ENT1 Ϫ/Ϫ mouse model. ENT1 Ϫ/Ϫ mice were generated in the laboratory of Dr. Doo-Sup Choi as described previously (10); ENT1 Ϫ/Ϫ mice were backcrossed with outbred WT C57BL/6 mice to generate ENT1 Ϫ/ϩ mice. Only ENT1 Ϫ/ϩ mice were crossed (producing ENT1 ϩ/ϩ , ENT1 ϩ/Ϫ , and ENT1 Ϫ/Ϫ offspring) to establish a breeding colony at the University of Western Ontario. Genotyping was done using isolated genomic DNA and standard PCR as previously described (9) . All aspects of this study were conducted in accordance with the policies and guidelines set forth by the Canadian Council on Animal Care and were approved by the Animal Use Committee of the University of Western Ontario.
METHODS

Materials
MVEC isolation/culture. MVECs were isolated as described previously for rats (2) , based on the affinity of their ␣-D-(ϩ)galactosyl residues for isolectin B4 from Bandeiraea simplicifolia (BSI-B4; Sigma) bound to magnetic microbeads (Dynabeads, M-450 Epoxy, Dynal, Lake Success, NY). The extensor digitorum longus muscles of female mice were removed from the hindlimbs under anesthesia by pentobarbital sodium (42 mg/kg ip). After careful removal and disposal of tissue containing larger blood vessels, the isolated muscle was sliced into ϳ0.5-mm pieces and digested for 30 -45 min in 0.84 mg/ml collagenase, 0.12 mg/ml trypsin and dispase, and 1.62 mg/ml BSA in 50 ml Krebs-Ringer solution containing (in mM) 127 NaCl, 4.6 KCl, 1.1 MgSO4, 1.2 KH2PO4, 8.3 D-glucose, 24.8 NaHCO3, 2 pyruvate, 11.4 creatinine, 20 taurine, 5 D-ribose, 2 L-asparginine, 2 L-glutamine, 1 L-arginine, and 0.5 uric acid in a 37°C water-jacketed organ bath bubbled with 95% O2-5% CO2. The enzymatic digest was filtered through 100-m nylon mesh to remove undigested fragments, and the dissociated cells were collected by centrifugation and washed in 37°C DMEM-F12 media. Cells were then resuspended with ϳ1 ϫ 10 6 BSI-B4 coated Dynabeads (in DMEM-F12 media) and rotated on a spindle for 10 -15 min. Endothelial cells bound to the magnetic beads were collected using a magnetic particle collector (MPC-1, Dynal), washed twice, and transferred to six-well plates in DMEM-F12 media supplemented with 20% FBS, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, 0.25 g/ml amphotericin B, 2 mM L-glutamine, 0.025 IU/ml heparin, and 125 g/ml ECGS and cultured at 37°C in a 5% CO2-95% room air humidified atmosphere. The media was changed routinely every 3 to 4 days, and the cells were passaged using 0.05% trypsin in 0.53 mM EDTA upon reaching confluence. After passage 3, the FBS and ECGS levels were reduced to 10% and 75 g/ml, respectively. The endothelial cell phenotype was confirmed by the presence of von Willebrand factor VIII and BSI-B4 antigens as described previously (2) . The cultures were typically found to contain Ͼ95% endothelial cells. In general, five passages were required to obtain sufficient cells to undertake the transport assays described herein.
In preparation for experimental assays, MVECs (passage 5-15) were trypsinized for 5 min at 37°C and then diluted with DMEM-F12 media ϩ 10% FBS and collected by centrifugation. The cells were washed once by resuspension/centrifugation in PBS containing (in mM) 137 NaCl, 6.3 Na2HPO4, 2.7 KCl, 1.5 KH2PO4, 0.9 CaCl2·2H2O, and 0. 3 H]substrate uptake was defined as the difference between the total uptake and that observed in the presence of dipyridamole. ENT1-mediated uptake was defined as that inhibited by 50 nM NBMPR. ENT2-mediated uptake was calculated as the difference between the uptake in the presence of 50 nM NBMPR and that seen in the presence of 10 M NBMPR/dipyridamole. In some cases, the cells were incubated with both adenine and dipyridamole to test for the dipyridamole-insensitive transporter-mediated uptake of 3 H]water for 3 min and then processing the samples as described above. An estimate of the extracellular water volume was obtained from extrapolation of the linear time courses of nonmediated uptake (in the presence of supermaximal concentrations of uptake blockers) back to zero time. In our hands, this method of assessing extracellular water space was more reliable than using membrane-impermeable tracers such as [ 14 digested with 7% perchloric acid for ϳ16 h. The acid soluble extract was removed and neutralized with an equal volume of 1 M potassium hydroxide and then centrifuged (10,000 g for 10 min) to remove insoluble precipitate. Extracts were stored at Ϫ20°C until required. The separation of purine nucleobases, nucleosides, and nucleotides was performed using two one-dimensional thin-layer chromatography methods modified from Metz et al. (19) (6 min . Plastic-backed PEI-cellulose F TLC plates (EMD Chemicals or Merck) were loaded with 10-l aliquots of neutralized extract and developed using the two solvent conditions in parallel. Purine metabolite locations were determined under UV light, and the Rf values were calculated and compared with standards for identification. The plates were then cut into 5-mm strips for liquid scintillation analysis of [ 3 H] content using Beckman Ready Protein ϩ scintillation fluid. Neither solvent system on its own was capable of separating all the purine metabolites of interest. The organic solvent (condition 2) was able to retard all nucleotides at the loading point on the plate and could clearly isolate adenosine and xanthine. However, the hypoxanthine and inosine spots overlapped. The LiCl gradient (condition 1), on the other hand, could isolate inosine effectively but produced a blended hypoxanthine-adenosine spot. Thus the amount of hypoxanthine was determined from the equation: dpm hypoxanthine ϭ dpm hypoxanthine/adenosine (condition 1) Ϫ dpm adenosine (condition 2). Since xanthine oxidase removes the tritium at the two position of 2,8-[
3 H]hypoxanthine to give 8-[ 3 H]xanthine, the dpm values associated with xanthine were doubled to compensate for this. 
Primers used for the amplification of each of the indicated genes are shown along with the expected product size and the number of cycles used in the PCR reactions. The cycle number was selected based on the lowest number that revealed a product up to a maximum of 35 cycles in the qualitative reverse-transcriptase PCR reactions. ENT, equilibrative nucleoside transporter; CNT, concentrative nucleoside transporter. Table 1 , and the products were resolved on 2% agarose gels. The same PCR conditions were used for each primer pair in both the WT and ENT1 Ϫ/Ϫ samples, and all amplifications shown on each gel set were done in parallel using the same WT and KO cDNA preparations. The first lane on each gel set represents the DNA ladder (bp sizes as labeled). Set 1: ENT1, ENT2, ENT3, and ␤-actin (the vertical bar indicates where a blank section of the gel image was removed between the ENT3 and ␤-actin lanes); set 2: adenosine A2a receptor, adenosine A2b receptor, A3 receptor, and ␤-actin; and set 3: adenosine kinase (ADK), adenosine deaminase (ADA), adenine phosphoribosyltransferase (ARPT), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), purine nucleoside phosphorylase (PNP), xanthine oxidase (XO), and ␤-actin. All products were of the expected size. B: quantitative real-time PCR: apparent differences in gene expression between the WT and ENT1 Ϫ/Ϫ samples, respectively. The gene-to-␤-actin ratios derived from each independent experiment were then averaged to obtain the data shown. Each bar is the mean Ϯ SE of 3 separate amplification runs from 2 independent mRNA isolations (N ϭ 6). *P Ͻ 0.05, significant difference in expression between the WT and ENT1
Ϫ/Ϫ cells (Student's t-test). C: data from B plotted as the relative change between the WT and ENT1 Ϫ/Ϫ mice.
Reverse-transcriptase polymerase chain reaction. Total RNA was isolated from the WT and ENT1
Ϫ/Ϫ MVECs using the phenolchloroform extraction. First-strand DNA template was generated using 5 g (MVECs) of DNaseI (Invitrogen, Carlsbad, CA)-treated total RNA and the Superscript First Strand Synthesis System for RT-PCR using oligo d(T) primers (Invitrogen).
RT-PCR amplifications were performed using Plantinum Taq DNA polymerase (Invitrogen) in a Thermocycler PE 480 (Perkin Elmer, Norwalk, CT) using an oil-overlaid 50-l reaction mixture in 500-l thin-walled reaction tubes. Reaction conditions included a 2-min 94°C initial activation, followed by 25, 30, or 35 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C. Preliminary experiments determined the number of cycles of PCR that were required to obtain a visible product on agarose gels for each of the transcripts while remaining on the log-linear portion of the cycle number versus product formation curves. PCR products were resolved by electrophoresis on 2% agarose gels against the O'GeneRuler 50-bp DNA ladder mix (Fermentas, Burlington, ON, Canada). Based on qualitative PCR, ENT1, ENT3, ADA, and the adenosine receptor A 2a and A3 genes were chosen for quantitative real-time PCR analysis using a Roche LightCycler (Hoffmann-La Roche, Mississauga, ON, Canada). ␤-Actin was chosen as a reference control. All primers used were the same as those for qualitative PCR. Standard curves for all transcripts were generated using the same cDNA preparation at concentrations ranging from 10 Ϫ7 to 10 Ϫ12 M. The PCR was conducted using 1 l of WT or knockout (KO) cDNA and SYBR Green Jumpstart Taq ReadyMix capillary formulation (Sigma). PCR conditions were as follows: initial denaturing at 94°C for 30 s, followed by 40 cycles of 94°C for 0 s, 55°C for 5 s, 72°C for 17 s, and 78°C for 1 s. The melting curve analysis of products at the end of the reaction revealed single products from each primer pair. At least three individual reactions were performed using two different cDNA preparations.
Primer sequences and expected sizes are summarized in Table 1 for ENT1; ENT2; ENT3; ENT4; concentrative nucleoside transporter subtypes 1 (CNT1), 2 (CNT2), and 3 (CNT3); adenosine kinase; ADA; adenine phosphoribotransferase; hypoxanthine-guanine phosphoribotransferase; purine nucleoside phosphorylase; xanthine oxidase; A 1, A2a, A2b, and A3 adenosine receptors; and ␤-actin.
Immunoblots. Extensor digitorum longus muscles were isolated from age-and sex-matched mice and quickly placed in ice-cold lysis buffer containing 20 mM Tris·HCl, 150 mM NaCl, 1 mM Na 2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na 3VO4, and 1 g/ml leupeptin (pH 7.5), supplemented with 1 mM phenylmethylsulfonyl fluoride just before use (Cell Signaling Technology, Pickering, ON, Canada). Total protein from tissue lysates (100 g for ADA and ENT3; and 200 g for adenosine receptor A2a and A3) was subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were incubated overnight (Ն12 h) at 4°C with one of the following primary antibody dilutions: ADA, 1:1,000; ENT3, 1:400; adenosine receptor A 2a, 1:1,000; or adenosine receptor A3, 1:200. Secondary antibodies were used at dilutions of 1:10,000, 1:1,000, 1:4,000, and 1:1,000 for ADA, ENT3, A 2a, and A3, respectively, and incubated with membranes for 1 h at room temperature. Detection was performed using LumiGLO chemiluminescent substrate (Cell Signaling Technology) and the VersaDoc Imaging System (Bio-Rad). After exposure, the membranes were stripped (200 mM glycine, 1% Tween-20, and 0.1% SDS; pH 2.2) and then probed for GAPDH using a 1:1,000 dilution of primary antibody for 2 h at room temperature. The secondary antibody was used at dilutions of 1:2,000 for ADA and ENT3 and 1:4,000 for adenosine receptor A 2a to account for the double amount of protein used. Densitometry was performed using ImageJ software (http:// rsbweb.nih.gov/ij/index.html). In all cases, the major protein detected by each antibody reflected the expected size of the product based on manufacturers' specifications and previously published data using these antibodies (8, 20) .
RESULTS AND DISCUSSION
The gross phenotype of the ENT1 Ϫ/Ϫ mice was similar to that reported previously by Choi and colleagues (10) . The ENT1 Ϫ/Ϫ mice had a consistently lower body weight. They were also notably easier to handle than WT mice (less distress because of handling), likely reflecting the anxiolytic phenotype reported previously (9) . Quantitative RT-PCR confirmed the loss of the full-length ENT1 transcript in the ENT1 Ϫ/Ϫ mice. MVECs were successfully isolated from the skeletal muscle tissue of WT and ENT1 Ϫ/Ϫ mice. MVECs from the ENT1 Ϫ/Ϫ mice had no detectable high-affinity binding sites for the ENT1-selective radioligand probe [ 3 H]NBMPR (Fig. 1) , confirming the specificity of this radioligand for the ENT1 protein.
WT mouse MVECs had 150,000 Ϯ 27,000 [ 3 H]NBMPR sites/ cell with an affinity of 0.09 Ϯ 0.02 nM, which is typical of NBMPR binding to ENT1. We found no evidence for Na ϩ -dependent CNT1, CNT2, and CNT3, and we confirmed that MVECs do not express the A 1 adenosine receptor subtype (14) . No changes were observed in the expression of the ENT2 subtype of plasma membrane-located nucleoside transporters in ENT1 Ϫ/Ϫ mice compared with littermate controls (Fig. 2A) , nor was the ENT4 transcript detected in either the WT or ENT1 Ϫ/Ϫ cells. Furthermore, no significant differences were noted in the expression of adenosine kinase, xanthine oxidase, HGPRT, adenine, hypoxanthine-guanine phosphoribotransferase, purine nucleoside phosphorylase, or A 2b adenosine receptors in the ENT1 Ϫ/Ϫ MVECs compared with WT controls (Fig. 2A) . However, MVECs from ENT1 Ϫ/Ϫ mice showed significant increases of 15 Ϯ 3-and 11 Ϯ 2-fold, respectively, in the expression of mRNA transcripts for ADA and A 2a adenosine receptors, relative to WT littermate controls (Fig. 2B ). There was a trend toward a decrease in adenosine A 3 receptor transcript in the ENT1 Ϫ/Ϫ mice, but this did not reach statistical significance and there was no corresponding change in A 3 receptor protein levels (Fig. 3) . Likewise, there was a small but significant increase in ENT3 transcript (Fig. 2B) , which was also not paralleled by an increase in ENT3 protein in skeletal muscle (Fig. 3) . This lack of correlation between changes in mRNA versus protein levels for these relatively low abundance transcripts may reflect posttranscriptional regulation of translation efficiency and protein processing. Attempts to measure ADA and A 2a adenosine receptor protein levels in the MVECs proved to be problematic. However, significant increases in ADA (2.1-fold) and adenosine A 2a receptor (2.4-fold) protein was evident by immunoblotting using the skeletal muscle tissue of ENT1 Ϫ/Ϫ mice from which the MVECs were derived, relative to WT mice (Fig. 3) .
These adaptive changes can be rationalized, from a cell homeostasis perspective, if one assumes that the loss of ENT1 is leading to a reduced efflux of adenosine (arising from ATP metabolism) from the MVECs. This would result in an increased cytoplasmic adenosine and a decreased extracellular adenosine in the ENT1 Ϫ/Ϫ compared with WT mice. The increase in ADA would lead to more adenosine metabolism to inosine, which may then be converted to either hypoxanthine or inosine monophosphate (1), thereby reducing intracellular adenosine. Adenosine has well-established vasodilatory (4) and anti-inflammatory activities (16) , mediated in part via extracellular adenosine A 2a receptors on vascular endothelial cells. Thus the increase in adenosine A 2a receptor expression Ϫ/Ϫ (B) mice were incubated for 5 or 15 s, respectively, with the indicated concentrations of [ 3 H]2-chloroadenosine. Parallel assays were conducted in the absence (total influx) and presence of either 50 nM NBMPR (NBMPR-resistant influx) or 10 M DY/NBMPR (nonmediated uptake) as described in Fig. 4 for [ 3 H]FB uptake. The total transporter-mediated uptake of substrate was calculated as the total influx minus the nonmediated component. The ENT2-mediated uptake was calculated as the NBMPR-resistant uptake minus the nonmediated component, and the ENT1-mediated uptake was estimated as the difference between the total uptake and that seen in the presence of NBMPR. Results are plotted as picomoles of [ 3 H]2-chloroadenosine accumulated per microliter of cell water per second (Vi, ordinate) against the concentration of [ 3 H]2-chloroadenosine used (abcissa). Each point is the mean Ϯ SE from 5 experiments. The transporter kinetic constants derived from these data are shown in Table 2 . may be compensating for the lower levels of adenosine-mediated signaling in the ENT1 Ϫ/Ϫ mice as a consequence of reduced extracellular adenosine concentrations. A previous study has also invoked lower extracellular adenosine levels as an explanation for the reduced A 1 adenosine receptor signaling observed in the brains of ENT1 Ϫ/Ϫ mice (10) . In contrast to our findings in MVECs, there does not appear to be a compensatory upregulation of adenosine A 2a receptors in cardiomyocytes isolated from the ENT1 Ϫ/Ϫ mice (22) , suggesting that different cell types respond differently to changes in adenosine bioavailability. With the consideration that adenosine receptor expression varies between different tissues and therefore adenosine has differing physiological effects in each tissue, the compensatory changes that would result from altered adenosine levels might be expected to differ in different tissues and cell types.
In terms of the ability to accumulate [ 3 H]substrates associated with ENT activity, the WT MVECs accumulated both [ 3 H]formycin B (Fig. 4) and [ 3 H]2-chloroadenosine ( Fig. 5 ) via two distinct Na ϩ -independent dipyridamole-sensitive processes ( Table 2 ). The majority (ϳ90%) of the substrate uptake in WT MVECs was inhibited by 50 nM NBMPR and hence was mediated by ENT1. The remainder of the uptake was inhibited by dipyridamole, but not NBMPR, and hence was mediated by ENT2. It is noteworthy that mouse MVECs are very different from rat MVECs where ENT2 mediates ϳ50% of the total nucleoside uptake (2). Thus one would expect an ENT1-selective inhibitor such as NBMPR to have a much greater effect on nucleoside levels in the cardiovasculature of mouse compared with its effects in rat.
The uptake of [ 3 H]formycin B (Fig. 4) and [ 3 H]2-chloroadenosine (Fig. 5) by MVECs was reduced dramatically in the cells derived from the ENT1 Ϫ/Ϫ mice ( Table 2 ). The initial rate of uptake of 10 M (Fig. 4) . Similar time courses were observed for [ 3 H]2-chloroadenosine uptake by the ENT1 Ϫ/Ϫ and WT MVECs (data not shown). These functional data are compatible with the lack of any change in the transcript levels of ENT2 in the ENT1 Ϫ/Ϫ mice (Fig. 2) . The V max of 2-chloroadenosine uptake in the ENT1 Ϫ/Ϫ mice (0.19 Ϯ 0.07 pmol·l Ϫ1 ·s Ϫ1 ) was actually significantly lower than the V max of ENT2-mediated 2-chloroadenosine uptake in the WT mice (1.2 Ϯ 0.5 pmol·l Ϫ1 ·s Ϫ1 ) (Fig. 5) .
All of the above studies were done in Na ϩ -free media to eliminate the potential influence of Na ϩ -dependent uptake of nucleosides (17) . MVECs do not appear to express any of the known CNTs. However, to determine whether there are any other Na ϩ -dependent mechanisms for the uptake of nucleosides operating in these cells, the rate of uptake of 10 M formycin B was compared in normal PBS and Na ϩ -free NMG buffer. These experiments indicated that the mouse MVECs had a small amount of Na ϩ -dependent formycin B uptake, but it represented only about 3% of the total uptake, and there was no difference in this component between the WT and ENT1 Ϫ/Ϫ mice (data not shown).
To further assess the ENT2-mediated component in the MVECs, the uptake of [ 3 H]hypoxanthine was examined after depleting the cells of ATP to reduce trapping of [ 3 H]hypoxanthine metabolites. ENT2 differs from ENT1 in that it accepts nucleobases, such as hypoxanthine, as substrates in addition to purine and pyrimidine nucleosides. It was apparent from the initial time course studies using 10 M hypoxanthine that mouse MVECs readily accumulated hypoxanthine via a saturable system that was relatively insensitive to dipyridamole but that was inhibited by adenine (Fig. 6 ). These data suggest that hypoxanthine was being accumulated via an ENT-independent transport process. When adenine (1 mM) is used to define the nonmediated uptake component, the WT mouse MVECs accumulated hypoxanthine with K m and V max estimates of 125 Ϯ 29 M and 16.5 Ϯ 3.8 pmol·l Ϫ1 ·s Ϫ1 , respectively, while ENT1 Ϫ/Ϫ cells had similar K m and V max values of 123 Ϯ 28 M and 11.6 Ϯ 2.1 pmol·l Ϫ1 ·s Ϫ1 , respectively. A dipyridamole-insensitive equilibrative nucleobase transporter subtype 1 (ENBT1) with similar characteristics as that described herein has recently been characterized by us in human MVECs (6) . Hypoxanthine is a metabolite of adenosine metabolism and would be produced in the endothelial cells under conditions of high adenosine release from surrounding cells, such as would occur during tissue ischemia (1, 11, 12) . This hypoxanthine is metabolized intracellularly by xanthine oxidase with the consequent production of reactive oxygen species. Reactive oxygen species are believed to play a role in mediating the endothelial dysfunction observed in various pathological conditions including diabetes and ischemia-reperfusion injury (5, 15, 23) . Therefore, understanding how MVECs handle hypoxanthine is important in the overall evaluation of purine metabolism in the vasculature. It appears that both mouse and human MVECs, which have low or no ENT2, respectively, rely heavily on this nucleobase transporter for the transfer of nucleobases across the cell membrane. Rat MVECs, on the other hand, which express high levels of ENT2 (which can transport nucleobases), do not appear to express ENBT1. Further studies on this novel nucleobase transport system are needed.
Interestingly, the apparent rate of [ 3 H]hypoxanthine influx tended to increase when cells from WT mice were incubated with the ENT blocker dipyridamole before the uptake measurements, particularly at higher (Ͼ100 M) concentrations of hypoxanthine (Fig. 7) . In contrast, dipyridamole had no effect on hypoxanthine uptake by ENT1 Ϫ/Ϫ MVECs. Given that part of the hypoxanthine uptake in the MVECs would be due to the activity of ENT2, one should actually expect to see a small decrease in hypoxanthine uptake in the presence of dipyridamole. One interpretation of these data is that dipyridamole was blocking the efflux of a metabolite of hypoxanthine via ENT1. In normal cell metabolism, hypoxanthine is typically formed as a metabolite of inosine and is efficiently metabolized by xanthine oxidase to xanthine or by HGPRT to inosine monophosphate such that there is little free hypoxanthine in cells. However, under the experimental conditions used in this study, where cells are exposed to high concentrations of hypoxanthine, it 3 H]hypoxanthine (abcissa). Parallel assays were conducted in the absence and presence of 1 mM adenine with or without the inclusion of 10 M DY as described in Fig. 6 . Results are plotted as the transporter-mediated uptake of substrate (in pmol per l of cell water accumulated per s; Vi, ordinate) after subtraction of the adenine-insensitive component. Each point is the mean Ϯ SE from 5 experiments. The transporter kinetic constants derived from these data are shown in Table 2 .
Fig. 8. MVECs isolated from WT and ENT1
Ϫ/Ϫ mice were depleted of ATP and incubated with 100 M [ 3 H]hypoxanthine in the absence and presence of 10 M DY for 20 min. Acid extracts of cell pellets were neutralized with 1 M KOH, and aliquots were subjected to thin-layer chromatography as described in the text. A repeated-measures ANOVA was performed within each metabolite group. *P Ͻ 0.05 compared with WT ϪATP condition; †P Ͻ 0.05 compared with WT ϪATP ϩDY condition.
